Introduction
The continuing high magnitude of the cancer incidence and the failure of treatments on cancers at advanced stage highlight the dire need for new approaches to control such diseases. Chemoprevention, which is a pharmacological approach to intervention in an effort to arrest or reverse carcinogenesis at tumor promotion stage, has become increasingly appreciated as a new strategy in the fight against cancer (1) (2) (3) . Since diverse compounds isolated from plants were reported to interfere with a specific stage of the carcinogenic process or possess immense oncological value, numerous efforts have been devoted to identifying such phytochemicals and phytochemical-derived agents with cancer preventive properties (4, 5) .
Chiliensisine A (Chel A), a novel styryl-lactone isolated from Goniothalamus cheliensis Hu, has been shown to possess potent cytotoxicity against human promyelocytic leukemia HL-60 cells (6) . Mechanically, Chel A was capable of inducing apoptosis of leukemia cell by downregulation of Bcl-2 expression (7).
Additionally, a recent study in our laboratory has demonstrated that Chel A also displayed profound cytotoxic effects against HCT116 colon cancer cell line (data not shown). These results together suggest the potential of Chel A as an agent for cancer chemotherapy. Yet there has been no exploration of Chel A for chemopreventive intervention thus far, to the best of our knowledge. Hence, the study here sought to evaluate the potential inhibitory effect of Chel A on EGF-induced cell transformation in JB6 Cl41 cell culture model. Anchorage-independent growth. Soft agar colony formation assay was performed as previously described (15) . Briefly, 2.5 ml of 0.5% agar in basal modified Eagle's medium (BMEM) supplemented with 10% FBS, and 20 ng/ml EGF, as well as Chel A, at indicated concentrations, was layered onto each well of 6-well tissue culture plates.
3×10
4 Cl41 cells or their stable transfectants were mixed with 1 ml of 0.5% agar BMEM supplemented with 10% FBS with or without 20 ng/ml EGF, as well as with or without Chel A, and layered on top of the 0.5% agar layer. The plates were incubated at 37 ℃ in 5% CO 2 for three weeks. The colonies were then counted under microscopy. Those with more than 32 cells were scored. The results were presented as colonies/10 4 seeded cells.
Western blottings. Cl41 cells, MEFs, and their transfectants were cultured in each well of 6-well plates with normal medium until they reached 70%-80% confluence.
Cell culture medium was replaced to medium with 0.1% FBS for 24 hours. Then the culture medium was changed to medium with 1% FBS and cells were treated with Chel A for 0. washed with ice-cold PBS, and then extracted with cell lysis buffer (10 mM Tris-HCl, pH 7.4, 1%SDS, 1mM Na3VO4, and proteasome inhibitor). The cell extracts were subjected to Western blotting with each of the antibodies for determination of PARP, Cleaved PARP, Caspase 3, Cleaved Caspase 3, p53, p-p53 ser15, p-MDM2 Ser166, p-Chk1 Ser345, Chk1, p-Chk2 Thr68 (Cell Signaling, Beverly, MA, USA), Catalase (Calbiochem, EMD Biosciences, Inc., La Jolla, CA, USA), MDM2, β-Actin (Sigma, St. Louis, MO, USA), as indicated. The protein bands specifically bound to the primary antibodies were detected using an alkaline phosphatase-linked secondary antibody and an ECF (enhanced chemifluorescence) Western blotting analysis system (Amersham Pharmacia Biotech, Piscataway, NJ, USA), as previously described (15) .
Reverse transcription polymerase chain reaction (RT-PCR).
Cl41 cells were cultured in 6-well plates until reaching 70%-80% confluence. Cell culture medium was changed to 0.1% FBS medium for 24 h. Then cells were exposed to Chel A using the same method as was used for the cells that were treated for Western blotting assay.
After treatment for the indicated time periods, total RNAs were extracted from cells using Trizol reagent (Invitrogen, Carlsbad, California, USA). Total cDNAs were synthesized by using oligdT (20) primer by SuperScript the mRNA amount of p53 and β-actin, respectively. The PCR products were separated onto 3% agarose gels, stained with EB, and scanned the images from a UV light as described previously (21).
Luciferase assay. Cl41 and its stable transfectant transfected with p53-promoter luciferase reporter plasmid were seeded into 96-well plates. The cell culture medium was replaced with 0.1% FBS MEM for 24 hrs, and then cells were exposed to Chel A at the indicated time periods and concentrations. The cells were then lysed for luciferase assay using luciferase substrate as previously described (21). p53, a tumor suppressor, has been reported to participate directly in the mediation of caspase-dependent apoptosis (25) . To explore the mechanism underlying Chel A-induced apoptosis, phosphorylation of p53 at ser15, which reflects its functional response to cellular stress and leads to apoptosis (26) , and total p53 protein expression were examined in Chel A-treated Cl41 cells, which express wild-type p53.
Western blot analysis revealed that Chel A treatment induced both p53 phosphorylation at ser15 and total p53 expression within as early as 1 hour and reaching maximum 3 hours ( Fig. 2A) , indicating that p53 participates in Chel A response. To further buttress this point, p53 phosphorylation and total expression were verified in MEF cells, which express wild-type p53. Chel A treatment upregulated levels of both Ser15 phosphorylated p53 and total p53 protein in MEF cells ( which is consistent with the results obtained from the Cl41cells. To determinate whether p53 activation is necessary for Chel A-induced apoptosis, we used p53 knockout cells. Western blot analysis showed that p53 protein expression was depleted in MEF p53-/-cells in compared with that in p53+/+ cells (Fig. 2C) .
Moreover, p53 knockout significantly abrogated Chel A-induced cleavage of PARP and caspase-3, suggesting that p53 was critical in Chel A-induced apoptosis (Fig. 2D ).
In addition, we also examined the Chel A's effect on EGFR activation. As shown in Fig. 2A , Chel A treatment elicited neither increased EGFR phosphorylation at Tyr1068, which is crucial to the EGF-induced Ras/MAPK activation (27) , nor elevated EGFR total protein expression, indicating that EGFR was not involved in Chel A-induced cell transformation inhibition and apoptotic induction.
Chel A specifically inhibited p53 protein degradation.
To elucidate the molecular mechanisms for Chel A upregulation of p53 protein expression, we first examined the effect of Chel A on p53 transcription by using Cl41 p53 promoter-driven luciferase reporter stable transfectant. As shown in Fig. 3A , Chel A treatment did not significantly promote p53 promoter-driven luciferase reporter activity, while UVB radiation significantly induced p53 promoter-driven luciferase activity, revealing that Chel A did not upregulate p53 at transcription level. Further, Chel A exerted no impact on p53 mRNA level within 6 hours along the time course by RT-PCR assay (Fig. 3B) . Thus, we anticipated that p53 induction by Chel A might be regulated at the protein degradation level or translational level.
In an attempt to clarify whether Chel A treatment is capable of preventing p53
Cancer Research. The effect of Chel A on the dynamic of p53 protein degradation was determined during the indicated time periods. As shown in Fig. 3C , the p53 protein level at 4 hrs in cells co-treated with Chel A and CHX is much higher than that observed in the cells treated with CHX alone, demonstrating that Chel A treatment significantly inhibited p53 protein degradation rate, further suggesting that Chel A treatment promoted p53 expression via inhibiting p53 protein degradation.
Chk1 mediated p53 stabilization and activation upon Chel A treatment
Several proteins, such as MDM2, Chk1, and Chk2, have been reported to be capable of regulating p53 protein degradation (26, 28) . MDM2 serves as a p53-specific E3 ubiquitin ligase functioning to mediating p53 protein degradation, by which MDM2 limits p53-induced apoptosis (28) . Posttranslational phosphorylation of the MDM2 protein at Ser166 promotes its mediation of p53 protein degradation (29) .
Thus, we examined whether Chel A had an effect on MDM2 phosphorylation at Ser166. The results showed that MDM2 total protein expression was not affected upon Chel A treatment, whereas its phosphorylation at Ser166 was increased in a time-dependent manner following Chel A treatment (Fig. 3D) . These data suggest that Chel A did not show any inhibition of MDM2 phosphorylation at Ser166, therefore did not account for accumulation of p53 protein upon Chel A treatment (Fig. 3D ).
Given the negative results received with MDM2, we then examined the kinases that can mediate p53 protein accumulation, such as Chk1 and Chk2 (30) . Chk1 and Chk2 are kinases capable of activating and stabilizing p53 protein by mediating phosphorylation of p53 protein, whereas the phosphorylation of Chk1 at Ser345 or of Chk2 at Thr68, is required for their activation (31) . Our results demonstrated that Chk1 phosphorylation at Ser345 was notably induced by Chel A treatment, whereas total Chk1 protein was slightly upregulated (Fig. 3D) . In contrast, the phosphorylation of Chk2 at Thr68 did not show marked alteration following Chel A treatment (Fig.   3D ). These results suggested that Chel A treatment might result in Chk1 phosphorylation and activation, subsequently mediating p53 stabilization.
To further substantiate this point, we analyzed protein levels of p53 protein phosphorylation and expression in the Chel A-treated Cl41 cells transfected with the plasmid encoding kinase inactive Chk1 mutant, GFP-Chk1 D130A, which can out-compete the endogenous Chk1 protein (17) . Verification of GFP-Chk1 D130A expression in Cl41 cells stably transfectant was shown in Fig 4A and ectopic expression of kinase inactive GFP-Chk1 D130A attenuated induction of p53 protein phosphorylation at Ser15 and expression by Chel A (Fig. 4B) , strongly indicating that Chk1 mediated p53 stabilization. Furthermore, GFP-Chk1 D130A expression abrogated cheliensisin A-induced cleavages of caspase-3 and PARP (Fig. 4C) , as well as inhibiting of EGF-induced Cl41 cell transformation (Figs. 4D and 4E ). 
Since reactive oxygen species (ROS) has been well-characterized as a positive regulator in activating Chk1 and p53 (32) , it is tempting to speculate whether ROS is also implicated in Chel A-induced Chk1 and p53 activation. Thus, two dyes, 2',7'-dichlorofluorescein diacetate (DCFH-DA) and hydroethidine (HE), were utilized to determine the intracellular hydrogen peroxide and superoxide anion following Cl41 treated with Chel A, as illustrated in Fig. 5A . As a result, the amount of hydrogen peroxide significantly increased upon Chel A exposure in a time-dependent manner (Fig 5B) , whereas the generation of superoxide was not observed under the same experimental conditions ( 
Discussion
Chemoprevention has become increasingly appreciated as a new strategy to fight against cancers. Discovering chemopreventive agents to reverse carcinogenesis is therefore of high significance (1-3) . Chel A, a novel styryl-lactone isolated from occur in more than 50% human cancers (33) . Despite being abrogated in some cancer types, p53 can become activated in response to a myriad of stress types, suggesting that activating p53 by targeting p53-related pathways is a potential strategy for cancer prevention and therapy (12) (13) (14) . In cancer harboring a WT p53, p53 often loses its function due to the degradation by overexpressed MDM2. Hence, targeting the p53-relavant pathway by reactivating its mutant or activating WT p53 could serve as an attractive strategy in both cancer prevention and therapy (34) (35) (36) . Previous study showed that Chel A could trigger apoptosis in human promyelocytic leukemia HL-60 cells, which are deficient of p53 expression (37) and are unlikely to examine Chel A's effect on p53-dependent pathway. In the current study, Cl41 cells and MEF cells with expression of wild-type p53 were utilized to explore whether Chel A could exert an impact on p53-associated anti-cancer effects. Our results strongly suggested that Chel A treatment could lead to both the accumulation and activation of p53 proteins. A-induced p53 stabilization may result from p53 phosphorylation at Ser15, because p53 phosphorylation at Ser15 can lead to a reduced interaction of p53 with its negative regulator MDM2 (28) . On the other hand, our data likewise suggested that MDM2 was activated due to its increased phosphorylation at Ser166. Although MDM2 activation would mediate p53 protein degradation, the overall p53 protein level is determined by multiple factors (26, 28) . The results in the current study presented the elevated total p53 protein levels in Chel A-treated cells, thus indicating that the force augmenting p53 protein stability, such as p53 phosphorylation at Ser15 by Chk1, outweighed that leading to p53 reduction. Cl41 cells were exposed to indicate concentrations of Chel A in combination with EGF for cell transformation assay in soft agar as described in Material and Methods.
Additional studies indicated that Chel
After being cultured in 37 ℃ with 5% CO 2 for 3 weeks, the colony formation was observed under inverted microscope and photographed (B). 
